Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FT596 + obinutuzumab
- Development stage
- Discontinued
- Lead developer
- Fate Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
FT596 + obinutuzumab is an investigational combination therapy consisting of FT596, an off-the-shelf, induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor natural killer (CAR NK) cell product targeting CD19, and obinutuzumab, an anti-CD20 humanized monoclonal antibody. FT596 is engineered to uniformly express an anti-CD19 CAR, a high-affinity, non-cleavable CD16 (FcγRIIIa) to enhance antibody-dependent cellular cytotoxicity (ADCC), and a fusion protein of IL-15/IL-15 receptor alpha for persistence and expansion. Obinutuzumab binds CD20 on B cells, enhancing direct and immune-mediated cytotoxicity, especially via NK cell activation and ADCC. The combination is under investigation for relapsed/refractory B-cell lymphoma and chronic lymphocytic leukemia, aiming to increase anti-tumor activity through dual targeting of B-cell antigens and enhancing NK cell-mediated immune responses[1][2][3].
- Other names
- Gazyva
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)FCGR3B (Fc gamma receptor III)CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on FT596 + obinutuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FT596 + obinutuzumab.